Reference - Detail
| RRC ID | 43640 |
|---|---|
| Author | Itonaga H, Tsushima H, Hata T, Matsuo E, Imanishi D, Imaizumi Y, Kawaguchi Y, Fukushima T, Doi Y, Mori S, Kamihira S, Tomonaga M, Miyazaki Y. |
| Title | Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa. |
| Journal | Int J Hematol |
| Abstract |
The T315I BCR-ABL mutation in chronic myelogenous leukemia (CML) patients is responsible for up to 20% of all clinically observed resistance. This mutation confers resistance not only to imatinib, but also to second-generation BCR-ABL tyrosine kinases, such as nilotinib and dasatinib. A number of strategies have been implemented to overcome this resistance, but allogeneic stem cell transplantation remains the only established therapeutic option for a cure. A 61-year-old male was diagnosed with Philadelphia chromosome-positive chronic-phase CML in 2002. He was initially treated with imatinib and complete cytogenetic response (CCyR) was achieved 12 months later. However, after 18 months, a loss of CCyR was observed and a molecular study at 24 months revealed a T315I mutation of the BCR-ABL gene. At 30 months, imatinib/interferon-alfa (IFNα) combination therapy was initiated in an effort to overcome the resistance. Thirty months later, he re-achieved CCyR, and the T315I BCR-ABL mutation disappeared at 51 months. To our knowledge, this is the first case report showing the effectiveness of imatinib/IFNα combination therapy for CML patients bearing the T315I BCR-ABL mutation. |
| Volume | 95(2) |
| Pages | 209-13 |
| Published | 2012-2-1 |
| DOI | 10.1007/s12185-012-1005-1 |
| PMID | 22262141 |
| MeSH | Antineoplastic Agents / administration & dosage Benzamides Drug Therapy, Combination Fusion Proteins, bcr-abl / genetics* Humans Imatinib Mesylate Immunologic Factors / administration & dosage Interferon-alpha / administration & dosage* Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy* Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics* Male Middle Aged Piperazines / administration & dosage* Point Mutation Pyrimidines / administration & dosage* Treatment Outcome |
| IF | 2.245 |
| Times Cited | 22 |
| WOS Category | HEMATOLOGY |
| Altmetric score |
オルトメトリクス指標項目
|
| The most frequently cited source | Patent(IFI CLAIMS) |
| Total number of mentions | 1 |
| Altmetric score changes over past 6months | 0.0 |
| Resource | |
| Human and Animal Cells | Ba/F3(RCB0895) |